Clinical

Dataset Information

0

Multi-parametric MRI for Therapeutic Response Prediction in Rectal Cancer


ABSTRACT: Interventions: Single arm prospective observationaI imaging biomarker study. Patients will have standard treatment, consisting of neoadjuvant chemoradiotherapy followed by surgery. There will be no change to the patient’s treatment by participating in this study. Patients participating in this study will have multi-parametric MRI and PET/CT at the following 3 time-points: 1. Prior to chemoradiotherapy 2. During the third week of chemoradiotherapy 3. Post chemoradiotherapy, within 1 week prior to surgery. A multi-parametric MRI incorporates standard morphological as well as diffusion weighted imaging and dynamic contrast enhanced sequences. The total follow-up duration will be 2 years from date of surgery. Primary outcome(s): Correlation of multi-parametric MRI (diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE)) at 3 Tesla with surgical histopathology tumour regression grade (TRG). Histopathological assessment will be performed on surgical specimens. TRG assessment will be performed as per the modified classification of Ryan et al set out in the AJCC Cancer Staging Manual, 7th Edition as follows: TRG 0 (complete response) - no viable cancer cells TRG 1 (moderate response) - single cells or small groups of cancer cells TRG 2 (minimal response) - residual cancer outgrown by fibrosis TRG 3 (poor response) - minimal or no tumour kill; extensive residual cancer. [At baseline pre-chemoradiotherapy, week 3 of chemoradiotherapy, and post-chemoradiotherapy (within 1 week prior to surgery) ]

DISEASE(S): Cancer-bowel-back Passage (rectum) Or Large Bowel (colon),Rectal Cancer

PROVIDER: 2464730 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2461578 | ecrin-mdr-crc
2014-09-01 | GSE58795 | GEO
2014-09-01 | E-GEOD-58795 | biostudies-arrayexpress
| 2470288 | ecrin-mdr-crc
| 2239387 | ecrin-mdr-crc
| 2215891 | ecrin-mdr-crc
2012-08-16 | E-GEOD-36562 | biostudies-arrayexpress
2018-09-26 | GSE120402 | GEO
2023-11-21 | PXD040451 | Pride
2012-08-16 | GSE36562 | GEO